R&D products - Suzhou Lixin Pharmaceutical Co., Ltd.

Products with valid patent protection will not be sold in countries where such products constitute patent infringement. At the same time, the liability for the applicability of the patent should rest solely with the importer.

Name	CAS	Treatment
Arbidol	131707-25-0	Double-effect anti-influenza various drug
Anamorelin Hydrochloride	861998-00-7	Cancer cachexia
Tirzepatide	2023788-19-2	Type 2 diabetes mellitus
Bazedoxifene	198481-32-2	Post–menopausalosteoporosis
Sitagliptin	486460-32-6	Type 2 diabetes
(R)-Lansoprazole	138530-94-6	Antipeptic ulcer medicine
Eltrombopag	496775-61-2	Thrombocytopenia in patients with chronic ITP
Larotrectinib	1223403-58-4	entity tumor
Baloxavir	1985605-59-1	Influenza A and B viruses
Cenicriviroc	497223-25-3	Nonalcoholic Steatohepatitis (NASH)
Sermaglutide	910463-68-2	Type 2 diabetes mellitus
Entrectinib	1108743-60-7	Entity tumor
Relugolix	737789-87-6	Prostate cancer, uterine fibroids
Linaclotide	851199-59-2	Irritable bowel syndrome
Choline Fenofibrate	856676-23-8	Hyperlipidemia control
Nerinetide	500992-11-0	Neuroprotection in patients with ischemic stroke
Difelikefalin	1024828-77-0	Chronic kidney disease associated pruritus (CKD AP) in adults undergoing hemodialysis